SHARP Business Systems (India) Pvt. Ltd, a wholly-owned Indian subsidiary of SHARP Corporation Japan, known worldwide for its unique technology products and solutions, today shared the results of a new study that verified the inhibitory effect of Plasmaclusterion technology (PCI) present in Sharp Air purifiers on respiratory diseases like asthma – a leading cause of morbidity and mortality in India.
The investigative research led by Dr.Munemasa Mori, an expert in respiratory medicine and stem cell research was carried out at the prestigious Columbia University Irving Medical Center, a prominent research institute in the United States. As part of the investigative study, researchers found a reduction in the marker linked with highly viscous mucus associated with impaired breathing in the respiratory tract of asthma patients and an increase in the marker linked with the smooth secretory protein related to low-viscosity mucus that helps improve breathing.
Commenting on the development, Narita Osamu, Managing Director, SHARP Business Systems (India) Pvt. Ltd said, ” Sharp air purifiers have already proven effective in identifying and removing toxic air pollutants from indoor air, and we’re consistently working with experts and institutions to study and improve the effectiveness of our products towards ensuring a clean and safe environment for everyone”.
